公开(公告)号：US20240299518A1

公开(公告)日：2024-09-12

申请号：US18663847

申请日：2024-05-14

申请人： CENTRO DE INMUNOLOGIA MOLECULAR

发明人： BELINDA SÁNCHEZ RAMÍREZ ,  GRETCHEN BÁEZ BERGADO ,  NARJARA GONZÁLEZ SUÁREZ ,  MABEL CRUZ RODRÍGUEZ ,  DIANA ROSA HERNÁNDEZ FERNÁNDEZ ,  LISSET CHAO GARCÍA

IPC分类号： A61K39/00 ,  A61P35/00

CPC分类号： A61K39/001106 ,  A61K39/001104 ,  A61P35/00 ,  A61K2039/55555 ,  A61K2039/585 ,  A61K2039/70 ,  A61K2039/82 ,  A61K2039/852

摘要： The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.

公开(公告)号：US12005104B2

公开(公告)日：2024-06-11

申请号：US17263290

申请日：2019-07-25

申请人： CureVac Netherlands B.V.

发明人： Ronald Hans Anton Plasterk

IPC分类号： A61K39/00 ,  C12Q1/6886

CPC分类号： A61K39/0011 ,  C12Q1/6886 ,  A61K2039/82

摘要： The invention relates to the field of cancer, in particular colorectal cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the APC, ARID1A, KMT2D, RNF43, SOX9, TCF7L2, TP53, and ZFP36L2 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

公开(公告)号：US20230414735A1

公开(公告)日：2023-12-28

申请号：US18311158

申请日：2023-05-02

申请人： BioNTech US Inc.

发明人： Michael Steven Rooney

IPC分类号： A61K39/00 ,  A61P35/04 ,  A61P35/00 ,  A61K45/06 ,  C07K14/47 ,  C12N9/00 ,  C07K14/705 ,  C07K4/12

CPC分类号： A61K39/001164 ,  A61P35/04 ,  A61P35/00 ,  A61K39/001103 ,  A61K39/001151 ,  A61K39/001108 ,  A61K39/001107 ,  A61K39/001163 ,  A61K39/001106 ,  A61K39/001162 ,  A61K39/001104 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/4748 ,  A61K39/001102 ,  A61K39/001134 ,  A61K39/001154 ,  C12N9/00 ,  C07K14/47 ,  C07K14/705 ,  C07K4/12 ,  A61K39/001152 ,  A61K2039/812 ,  A61K2039/836 ,  A61K2039/5158 ,  A61K2039/82 ,  A61K2039/505 ,  A61K2039/828 ,  A61K2039/804 ,  A61K38/00

摘要： The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

公开(公告)号：US20230220063A1

公开(公告)日：2023-07-13

申请号：US16624130

申请日：2018-06-22

申请人： NOVARTIS AG

发明人： Monica LIGUEROS-SAYLAN ,  Patrice MATCHABA ,  Tom THUREN ,  Paul RIDKER ,  Peter LIBBY ,  Penelope OTTEWELL ,  Yang Yi LAU ,  Margaret DUGAN

IPC分类号： C07K16/24 ,  A61K39/00 ,  A61P35/00 ,  A61K9/00 ,  G01N33/574

CPC分类号： C07K16/245 ,  A61K9/0019 ,  A61K39/00114 ,  A61P35/00 ,  G01N33/57423 ,  A61K31/282 ,  A61K2039/54 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/868

摘要： Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.

公开(公告)号：US20170253633A1

公开(公告)日：2017-09-07

申请号：US15445461

申请日：2017-02-28

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： C07K7/08 ,  C07K16/18 ,  G01N33/68 ,  A61K35/17 ,  A61K39/00 ,  C12N15/115 ,  C07K7/06 ,  C07K14/725

CPC分类号： C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16 ,  G01N33/6893 ,  G01N2800/52

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12084522B2

公开(公告)日：2024-09-10

申请号：US17339157

申请日：2021-06-04

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC分类号： C07K16/18 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  G01N33/68 ,  A61K35/12

CPC分类号： C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C12N15/115 ,  G01N33/6893 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K2319/00 ,  C12N2310/16 ,  G01N2800/52

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230405102A1

公开(公告)日：2023-12-21

申请号：US18311155

申请日：2023-05-02

申请人： BioNTech US Inc.

发明人： Michael Steven Rooney

IPC分类号： A61K39/00 ,  A61P35/04 ,  A61P35/00 ,  A61K45/06 ,  C07K14/47 ,  C12N9/00 ,  C07K14/705 ,  C07K4/12

CPC分类号： A61K39/001164 ,  A61P35/04 ,  A61P35/00 ,  A61K39/001103 ,  A61K39/001151 ,  A61K39/001108 ,  A61K39/001107 ,  A61K39/001163 ,  A61K39/001106 ,  A61K39/001162 ,  A61K39/001104 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/4748 ,  A61K39/001102 ,  A61K39/001134 ,  A61K39/001154 ,  C12N9/00 ,  C07K14/47 ,  C07K14/705 ,  C07K4/12 ,  A61K39/001152 ,  A61K2039/812 ,  A61K2039/836 ,  A61K2039/5158 ,  A61K2039/82 ,  A61K2039/505 ,  A61K2039/828 ,  A61K2039/804 ,  A61K38/00

摘要： The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

公开(公告)号：US11723956B2

公开(公告)日：2023-08-15

申请号：US16327543

申请日：2017-08-31

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  UNIVERSITÉ DE PARIS ,  Assistance Publique—Hopitaux de Paris ,  Ecole Nationale Superieure de Chimie de Paris ,  Universite de Versailles—St Quentin en Yvelines

发明人： Robert Malafosse ,  Nathalie Mignet ,  Vincent Boudy ,  Johanne Seguin ,  Kathia Lemdani ,  Claude Capron

IPC分类号： A61K38/19 ,  A61K39/07 ,  A61K41/00 ,  A61K47/10 ,  A61K47/36 ,  A61P35/00 ,  A61K47/34 ,  A61K9/00 ,  A61K39/04 ,  A61K9/06 ,  C07K16/28 ,  A61K31/765 ,  A61K39/395 ,  A61K38/38 ,  A61K39/00

CPC分类号： A61K38/193 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/765 ,  A61K38/385 ,  A61K39/04 ,  A61K39/07 ,  A61K39/39541 ,  A61K41/0028 ,  A61K41/0052 ,  A61K47/10 ,  A61K47/34 ,  A61K47/36 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/522 ,  A61K2039/54 ,  A61K2039/55522 ,  A61K2039/585 ,  A61K2039/82 ,  C07K2317/76 ,  A61K39/39541 ,  A61K2300/00

摘要： The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

公开(公告)号：US11672850B2

公开(公告)日：2023-06-13

申请号：US17729290

申请日：2022-04-26

申请人： Think Therapeutics, Inc.

发明人： David Kenneth Gifford ,  Brandon Carter

IPC分类号： A61K39/00 ,  A61K38/00 ,  A61K38/10 ,  A61K38/08 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K7/06 ,  C07K7/08 ,  A61P35/00 ,  A61K48/00

CPC分类号： A61K39/00116 ,  A61K38/08 ,  A61K38/10 ,  A61K39/001152 ,  A61K39/001158 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  A61K48/00 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86

摘要： Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

公开(公告)号：US20190111123A1

公开(公告)日：2019-04-18

申请号：US15740622

申请日：2016-06-29

申请人： UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

发明人： Nobuyuki MATOBA ,  Keegan BALDAUF ,  Joshua ROYAL

IPC分类号： A61K39/02

CPC分类号： A61K39/107 ,  A61K39/39 ,  A61K2039/542 ,  A61K2039/55544 ,  A61K2039/58 ,  A61K2039/82 ,  C07K14/28

摘要： Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.